“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
What happened
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
Why it matters
The development may change operating conditions or market expectations around AI. Further confirmation and measurable outcomes matter.
Affected entities
View evidence
1 reports · 1 original report · 1 independent
- TechCrunch AIPrimary source · Supports · EN · 100%“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z ↗
Claims
- “We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z Observed
Conflicts
No material conflict detected in the available evidence.
Timeline
- First reported
Market move following event
Market reaction is not yet available for this asset and time window.